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increased risk of colorectal cancer (CRC) compared with the
general population, and risk is higher among those who
received an organ transplant. We performed a cost-
effectiveness analysis to determine optimal CRC screening
strategies for patients with cystic ﬁbrosis. METHODS: We
adjusted the existing Microsimulation Screening Analysis-Colon
model to reﬂect increased CRC risk and lower life expectancy in
patients with cystic ﬁbrosis. Modeling was performed sepa-
rately for individuals who never received an organ transplant
and patients who had received an organ transplant. We
modeled 76 colonoscopy screening strategies that varied the
age range and screening interval. The optimal screening strat-
egy was determined based on a willingness to pay threshold of
$100,000 per life-year gained. Sensitivity and supplementary
analyses were performed, including fecal immunochemical test
(FIT) as an alternative test, earlier ages of transplantation, and
increased rates of colonoscopy complications, to assess if
optimal screening strategies would change. RESULTS: Colo-
noscopy every 5 years, starting at an age of 40 years, was the
optimal colonoscopy strategy for patients with cystic ﬁbrosis
who never received an organ transplant; this strategy pre-
vented 79% of deaths from CRC. Among patients with cystic
ﬁbrosis who had received an organ transplant, optimal colo-
noscopy screening should start at an age of 30 or 35 years,
depending on the patient’s age at time of transplantation.
Annual FIT screening was predicted to be cost-effective for
patients with cystic ﬁbrosis. However, the level of accuracy of
the FIT in this population is not clear. CONCLUSIONS: Using a
Microsimulation Screening Analysis-Colon model, we found
screening of patients with cystic ﬁbrosis for CRC to be cost
effective. Because of the higher risk of CRC in these patients,
screening should start at an earlier age with a shorter screening
interval. The ﬁndings of this study (especially those on FIT
screening) may be limited by restricted evidence available for
patients with cystic ﬁbrosis.Abbreviations used in this paper: CRC, colorectal cancer; FIT, fecal
immunochemical test; ICER, incremental cost-effectiveness ratio; LYG,
life-years gained; MISCAN-Colon, Microsimulation Screening Analysis-
Colon.Keywords: Colonoscopy Screening; Microsimulation Modeling;
Screening Ages; Decision Analysis.
ystic ﬁbrosis is the most common, life-shortening,Most current article
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https://doi.org/10.1053/j.gastro.2017.10.036Cautosomal recessive genetic disease among
whites.1 Approximately 35,000 children and adults have
cystic ﬁbrosis in the United States (US), with worldwide
prevalence estimated in more than 70,000 individuals.2,3Cystic ﬁbrosis is caused by a mutation in the cystic
ﬁbrosis transmembrane conductance regulator gene. Cystic
ﬁbrosis impacts multiple organ systems, including respira-
tory and gastrointestinal.4 Because of advances in disease
management, detection, and therapy, survival has increased
in individuals with cystic ﬁbrosis. The median predicted
survival age increased from 33.3 to 41.7 years between
2000 and 2015, and currently more than half of individuals
with cystic ﬁbrosis are aged 18 or older.4 However, with
improved survival, individuals with cystic ﬁbrosis increas-
ingly become at risk for other diseases that typically occur
at older ages, especially those involving the gastrointestinal
tract.5
Gastrointestinal malignancies are an emerging health
problem among individuals with cystic ﬁbrosis. Several
studies have shown an increased risk of digestive tract
cancers and an increased early incidence and progression
of adenomatous colorectal polyps to colorectal cancer
(CRC).5–8 Screening for CRC is a well-established interven-
tion that has been shown to reduce the burden of CRC in the
general population.9–17 Screening generally starts at the age
of 50 for the average risk population, with those at higher
risk (such as those with family history of CRC [ﬁrst-degree
relatives] or Lynch syndrome) commencing at an earlier
age.18 Although those with cystic ﬁbrosis fall into the latter
category (their CRC risk exceeds that of those with
ﬁrst-degree relatives), their lower life expectancymay lead to
a different trade-off between the beneﬁts and harms of CRC
screening. At present, there are no speciﬁc recommendations
for screening and surveillance for this population.
We performed a decision analysis for the Cystic Fibrosis
Foundation and Cystic Fibrosis CRC Screening Task Force,19
to explore the beneﬁts, harms, and costs of CRC screening in
the CF population and determine the most appropriate CRC
screening strategy using a modeling approach.
EDITOR’S NOTES
BACKGROUND AND CONTEXT
Individuals with Cystic Fibrosis have shown to be at
increased risk of colorectal cancer compared to general
population. Although they are at higher risk or colorectal
cancer, at present there are no speciﬁc screening
recommendations for this population.
NEW FINDINGS
Using a MISCAN-Colon microsimulation model,
researchers found that screening in these patients
should start at an earlier age with a shorter screening
interval compared to the general population.
LIMITATIONS
The ﬁndings of this study (especially those on FIT
screening) may be limited by restricted evidence
available for patients with cystic ﬁbrosis.
IMPACT
Colorectal cancer screening in individuals with Cystic
Fibrosis is likely cost effective.
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We used the Microsimulation Screening Analysis-Colon
(MISCAN-Colon) model (Erasmus University Medical Center,
Rotterdam, The Netherlands) to assess the effectiveness and
costs of screening for CRC among individuals with cystic
ﬁbrosis. This model is part of the Cancer Intervention and
Surveillance Modeling Network.20
MISCAN-Colon Model Description
MISCAN-Colon is a well-established stochastic micro-
simulation model for CRC. The structure, underlying assump-
tions, and calibration of this model have been described in
previous studies and in the Supplementary model.20,21 Brieﬂy,
MISCAN-Colon simulates the life histories of many individuals
from birth to death (ﬁrst without screening and subsequently
with screening). As each simulated individual ages, zero, 1, or
more than 1 adenomas may develop. These adenomas can
progress in size and may develop into (preclinical) cancer.
Survival after cancer diagnosis depends on age, stage, and the
localization of the cancer at diagnosis.22 The introduction of
screening may alter the simulated life histories: detection and
removal of adenomas may prevent some cancer cases or may
detect others at an earlier stage (favorable survival). MISCAN-
Colon quantiﬁes the effectiveness and the costs of screening
by comparing all the life histories with screening with the
corresponding life histories without screening.
MISCAN-Colon was ﬁrst calibrated to age-, stage-, and
localization-speciﬁc incidence of CRC as seen in the US general
population in the SEER (Surveillance, Epidemiology, and End
Results) program before the introduction of the screening
(years between 1975 and 1979, Supplementary Figure 1)23
and the age-speciﬁc prevalence distribution of adenomas seen
in autopsy studies (Supplementary Figure 2).24–33 Adenoma
dwell time and the preclinical duration of CRC were calibrated
to the outcomes of the randomized clinical trials evaluating
screening using guaiac fecal occult blood tests and
sigmoidoscopy.9–12,14,34Adaptions of the MISCAN-Colon Model to the
Cystic Fibrosis Population
The MISCAN-Colon model was adjusted to reﬂect the
increased CRC risk and the elevated all-cause mortality in in-
dividuals with cystic ﬁbrosis. Modeling was performed sepa-
rately for individuals who never received a transplant and
those who were post-transplant to account for differences in
CRC risk and survival between these 2 groups (non-transplant
vs transplant patients). We assumed that the higher CRC risk in
both groups was caused by a more frequent adenoma onset
(increased probability of adenoma occurrence across all ages),
which would result in more CRC.
For individuals with cystic ﬁbrosis who have not had a
transplant, the parameters of the model were adjusted to
replicate the 7-fold higher CRC risk observed in a 20-year study
of 48,188 individuals with cystic ﬁbrosis included in the Cystic
Fibrosis Foundation Patient Registry (Figure 1).6 Adenoma and
advanced adenoma (ie, large adenoma  10 mm) detection
rates at 2 different screening rounds were computed and
compared with the adenoma detection rates observed in an
observational study of people with cystic ﬁbrosis undergoing
colonoscopy screening (Supplementary Figure 3).8 The model
was also adjusted to reﬂect the overall mortality of individuals
with cystic ﬁbrosis in 2015.4
In all analyses for cystic ﬁbrosis transplant patients, we
assumed the same adenoma risk as the non-transplant cystic
ﬁbrosis population until organ transplantation. We assumed a
more frequent onset of adenomas immediately after organ
transplant. A 30-fold increase in CRC risk was based on the US
cohort study by Maisonneuve et al6 (Figure 1). Simulated ad-
enoma and advanced adenoma detection rates were computed
and are reported in Supplementary Figure 3. In addition to a
higher CRC risk, we also assumed that transplanted individuals
with cystic ﬁbrosis had a higher risk of dying of CRC once
diagnosed. The increased CRC death-speciﬁc risk was modeled
as a hazard ratio of 2 based on the excess risk of CRC death
using the model provided by Rutter et al.22 Life expectancy post
transplantation was based on life tables for individuals with
cystic ﬁbrosis after lung transplantation. Lung transplants
constitute 90% of transplantations in individuals with cystic
ﬁbrosis.4 Our model reﬂected the International Society for
Heart and Lung Transplantation’s data, which shows that for
individuals with cystic ﬁbrosis post-transplant survival is
related to time since the transplant and not age.35 We simu-
lated this entire population with transplant at the age of
30 years (the median age of transplant) and assessed earlier
ages of transplantation in sensitivity analyses to assess if the
optimal screening strategies would change.Screening Strategies Simulated
For both groups (transplant and non-transplant individuals
with cystic ﬁbrosis), a cohort of 10 million individuals, aged 30
years in 2017, was simulated with the adjusted MISCAN-Colon
model under 76 different colonoscopy screening strategies (a
total of 152 different screening strategies). The strategies
differed with respect to (i) screening interval (3, 5, or 10 years
for colonoscopy; (ii) age to start (30, 35, 40, 45, 50 years); and
(iii) age to end screening (55, 60, 65, 70, 75 years). Further-
more, an additional cohort of 10 million individuals aged 30
years in 2017 without cystic ﬁbrosis was simulated to enable a
Figure 1. CRC incidence expected in individuals with cystic
ﬁbrosis according to Maisonneuve et al. 2013 and CRC
incidence simulated in the MISCAN-Colon model without
screening in the US general population, non-transplant, and
transplant cystic ﬁbrosis patients assuming a higher CRC risk
through a more frequent adenoma onset (base case analysis).
Note: Bars indicate 95% conﬁdence intervals; CRC, colo-
rectal cancer; CF, cystic ﬁbrosis.
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and the US general population under the recommended US CRC
screening guidelines (colonoscopy starting at age 50, repeated
every 10 years).
In addition, given that colonoscopy might be very
demanding for individuals with cystic ﬁbrosis, we explored the
fecal immunochemical test (FIT) as a possible and hypotheti-
cally adequate alternative in this population. As such, we per-
formed a speciﬁc supplementary analysis including also annual
FIT screening (25 screening strategies).Screening Assumptions
Test characteristics and complication rates for each
screening test were based on studies in the general population
(Supplementary Table 1)36–40 because speciﬁc information for
the cystic ﬁbrosis population is not available.
Modeling FIT screening strategies, we assumed that pa-
tients with a positive FIT result were referred for a diagnostic
colonoscopy (positive threshold: 100 ng/ml buffer, equals to
20 mg/g feces).37 Individuals with adenomas detected and
removed during a screening or diagnostic colonoscopy were
assumed to enter colonoscopy surveillance according to the
current general population guidelines,18 except for colonoscopy
screening strategies with 3-year screening interval where a
more intensive colonoscopy surveillance interval was intro-
duced in line with the screening interval: every 3 years. We
assumed 100% adherence to screening, diagnostic, and sur-
veillance tests.
Because it is reasonable to consider that the performance of
CRC screening in the cystic ﬁbrosis population may be different
with regards to colonoscopy complications, adverse events
related to a more intensive bowel preparation, and the efﬁcacyof FIT, we address these aspects in speciﬁc sensitivity analyses
to assess if the optimal screening strategies would be affected.CRC Screening Costs and Outcomes
The cost-effectiveness analyses were carried out from a
societal perspective. The costs of screening tests were based on
the 2014 Medicare payment rates including co-payments
(Supplementary Table 2). Complication costs were obtained
from a cost analysis study of cases hospitalized after endoscopy
in 2007.41 Patient time costs were added to both.42 The cost of
life-years with CRC care were based on the SEER-Medicare
linked data analysis and included co-payments and patient
time costs.43 All costs were adjusted to 2015 using the annual
average Consumer Price Indexes provided by the US Bureau of
Labor Statistics.44 For each simulated cohort, we computed the
effectiveness (ie, CRC cases prevented, CRC deaths prevented,
and life-years gained [LYG]) and costs of the screening. LYG
from screening and costs were discounted by applying the
conventional 3% annual discount rate.Cost-effectiveness Analyses
We determined the cost-effectiveness of each screening
strategy and compared these results with no screening. Sub-
sequently, we performed an incremental cost-effectiveness
analysis to determine the optimal screening strategy. To do
this we: (i) ranked all the screening strategies by increasing
costs; (ii) excluded all the screening strategies that were more
costly and less effective than other strategies (“strongly domi-
nated strategies”); (iii) deleted the screening strategies that
were less costly and less effective than another but provided an
additional life-year at higher incremental costs (“weakly
dominated strategies”); (iv) calculated for all remaining stra-
tegies (“efﬁcient strategies,” or strategies on the “efﬁcient
frontier”) the incremental cost-effectiveness ratio (ICER) as the
ratio between additional costs and additional clinical beneﬁts
(in this case, LYG) of a speciﬁc screening strategy compared
with the previous less expensive strategy (ie, strategy with
costs lower and closest to the strategy of interest); and (v)
selected the optimal strategy assuming a willingness to pay
threshold of $100,000 per LYG.Sensitivity Analyses
We conducted multiple sensitivity analyses to test the
robustness of the model results under a variety of different
assumptions. These assumptions included: (i) lowering colo-
noscopy test sensitivity for small and medium size adenomas
(0.65 and 0.80, respectively); (ii) a more proximal CRC location
(50% of CRC in the right colon); (iii) increasing colonoscopy
complication rates 2-fold; (iv) increasing the risk of cardio-
vascular complications associated with colonoscopy (5- and
10-fold increased risk, including respiratory arrest); (v)
lowering FIT speciﬁcity (0.90); (vi) a worst case for FIT
considering a lower speciﬁcity (0.75) and sensitivity (ie, 36%
reduced) in cystic ﬁbrosis population (different FIT perfor-
mances); (vii) biennial screening intervals for FIT; (viii)
lowering adherence to the screening test (80%); (ix) more
intensive colonoscopy surveillance (3 years) for all the
screening strategies; and (x) increasing costs because of
increased patient time (Supplementary Table 2).
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ﬁbrosis, we analyzed the impact of: (i) a higher CRC risk
(10-fold increased risk compared with general population);
(ii) a higher CRC risk (7-fold) because of a shorter adenoma
dwell time (94% reduced, extremely fast adenoma progression)
instead of a more frequent adenoma onset (Supplementary
Figure 4); and (iii) a higher all-cause mortality in older ages
( 45 years).45 For the individuals with cystic ﬁbrosis who
have had a transplant, we investigated the impact of: (i) dif-
ferential age at transplant (20 and 25 years old in 2017);
(ii) additional colonoscopy screening strategies (starting at age
32, every 5 years); (iii) increased CRC risk (45-fold increased
risk) with a more proximal CRC location (50% of CRC in the
right colon); (iv) utilization of the same age-speciﬁc mortality
rate observed among non-transplant individuals with cystic
ﬁbrosis after age 50 years; and (v) higher CRC risk because of a
combination of shorter adenoma dwell time (50% reduced) and
higher adenoma onset (16-fold increased risk calibrated to
replicate the increased CRC incidence among these individuals;
Supplementary Figure 4).Results
Without screening, the model predicted 19.1 CRC deaths
per 1000 30-year-old individuals with cystic ﬁbrosis who
have not had a transplant. Among those who had a trans-
plant, 22.3 CRC deaths per 1000 individuals were predicted
to die from CRC (Table 1). The recommended US CRC
screening strategy was estimated to prevent more than
73% of the CRC deaths among the US general population,
66% of CRC deaths among individuals with cystic ﬁbrosis,
and 39% of individuals with cystic ﬁbrosis post-transplant.
However, only 22% of individuals who received a trans-
plant and 36% of those who did not were predicted to
survive in the model until age 50, thereby meeting the age
requirement to participate in this screening strategy
(Figure 2).Table 1.Number of Colorectal Cancer (CRC) Deaths Predicted,
Microsimulation Screening Analysis-Colon Model With
for the US General Population, for Transplant and Non
Screening strategies CRC deaths predicteda CRC
US general population:
Without screening 27.8
Colonoscopy, Ages 50–75 (10) 7.4
No transplant CF patients:
Without screening 19.1
Colonoscopy, Ages 50–75 (10) 6.5
Transplant CF patients:
Without screening 22.3
Colonoscopy, Ages 50–75 (10) 13.6
CRC, colorectal cancer; LYG, Life-years gained compared with
aThese values were computed per 1000 30-year-old US individ
2017, and 1000 30-year-old transplant CF patients (with organ
population, no transplant, and transplant CF patients.
bLYG from screening were discounted (3%).The costs and beneﬁts of all simulated screening strategies
for transplant and non-transplant individuals with cystic
ﬁbrosis were investigated (Supplementary Tables 3–6) and
strategy-speciﬁc efﬁcient frontiers are reported in Figure 3.
Among the efﬁcient colonoscopy screening strategies, LYG
from screening varied from 29 to 57 (per 1000 individuals 30
years of age) for non-transplant and from 28 to 64 for trans-
plant cystic ﬁbrosis patients. Higher beneﬁts were associated
with colonoscopy screening every 3 years from age 30 to 75,
while the lower values for LYG for individuals with cystic
ﬁbrosis with and without organ transplant were observed,
respectively, screening with once-lifetime colonoscopy at age
50 and 10-yearly colonoscopy from age 45 to 55.
For non-transplant individuals with cystic ﬁbrosis, when
only colonoscopy was considered as a screening test, the
optimal colonoscopy strategy was 1 screen every 5 years
from 40 to 75 years of age with an ICER of $84,000 per LYG
(Table 2). This strategy predicted 25 CRC cases and 4 CRC
deaths to occur, equating to a reduction of 52% in CRC
incidence and 79% for CRC mortality (Table 2). Among
transplanted cystic ﬁbrosis patients, colonoscopy screening
repeated every 3 years between ages 35 and 55 was
optimal, preventing 82% of CRC mortality (ICER of $71,000
per LYG) compared with no screening (Table 3).
When both FIT and colonoscopy screening strategies
were jointly modeled (Supplementary analysis), the optimal
screening strategy was annual FIT between age 35 and 75
years with an ICER of $47,000 per LYG (Table 2) for non-
transplant individuals with cystic ﬁbrosis. When compared
with no screening, it could prevent 31% of CRC cases and
78% of the CRC deaths (16 CRC cases and 15 deaths per
1,000). FIT was also cost-effective for cystic ﬁbrosis in-
dividuals who had undergone organ transplant with annual
FIT between ages 30 and 60, achieving a reduction in CRC
incidence of 20% and mortality of 77% with an ICER of
$86,000 per LYG (Table 3).Prevented, and Screening LYG Estimated With
out Screening and With Recommended Screening Scenarios
-transplant cystic ﬁbrosis patients
deaths preventeda Reduction in CRC mortality (%) LYGa,b
– – –
20.4 73.4 56.0
– – –
12.6 66.0 30.3
– – –
8.7 39.0 14.5
no screening; (n), screening interval; CF, cystic ﬁbrosis.
uals in 2017, 1000 30-year-old no-transplant CF patients in
transplant at age 30) in 2017 for, respectively, US general
Figure 2. Cumulative risk (%) of death for all causes simu-
lated with MISCAN-Colon model for US general population,
transplant, and non-transplant cystic ﬁbrosis patients without
screening. CF, cystic ﬁbrosis.
Figure 3. Efﬁcient frontiers with efﬁcient screening strategies
for non-transplant cystic ﬁbrosis and transplant cystic ﬁbrosis
patients. Total costs and LYG from screening were dis-
counted (3% discounting rate) and 100% adherence was
assumed for screening, diagnostic, and surveillance test.
Optimal screening strategies are labelled and indicated by
arrows.
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For many of the sensitivity analyses, the optimal
screening strategy remained the same as the base case
(Table 4). For non-transplant individuals with cystic
ﬁbrosis, the optimal age to stop colonoscopy screening was
sensitive to our assumptions for higher all-cause mortality
in older ages (55 years) or increased risk of cardiovascular
complications (70 years). A colonoscopy screening interval
of every 3 years was more optimal when adenoma dwell
time was reduced and CRC risk was increased with more
proximal adenoma location. Higher costs for colonoscopy
(more time required for patients to be prepared for colo-
noscopy and to recover from its complications) resulted in a
later age to start screening (45 years). When all strategies
were investigated (Supplementary analysis), FIT start age
was earlier (30 years) when adenoma dwell time was
shortened and CRC risk was increased. A reduction in
speciﬁcity and sensitivity of FIT increased the age of starting
screening to 40 years. FIT screening should stop at age 60,
when higher overall mortality was assumed among in-
dividuals with cystic ﬁbrosis in older ages. FIT was not
cost-effective when a biennial interval was considered.
Among transplant cystic ﬁbrosis patients, less intense
colonoscopy screening (every 5 years) was optimal when
higher patient time costs were considered. For individuals
with cystic ﬁbrosis who had an organ transplant before age
30, colonoscopy screening was optimal from 30 years.
However, optimal screening interval varied according to the
age at organ transplant: every 10 years up to age 55 for
those with transplantation at age 20; and every 5 years up
to age 55 for those who had a transplant at age 25. When we
assumed that older individuals with cystic ﬁbrosis who had
an organ transplant ( 50 years) had the same overall
mortality as the non-transplant, the age to stop screening
increased to 60 years of age. Considering all screening
strategies (Supplementary analysis), FIT screening was notconsidered cost-effective when there was an increased CRC
risk (45-fold), a shorter adenoma dwell time, biennial FIT,
lower FIT sensitivity and speciﬁcity, and when the same
age-speciﬁc mortality of non-transplant cystic ﬁbrosis in-
dividuals (for those older than 50 years) were assumed for
transplant cystic ﬁbrosis patients. Optimal screening stra-
tegies among these individuals also varied according the age
of organ transplant: FIT screening should start at age 25
when individuals with cystic ﬁbrosis underwent trans-
plantation at age 20 or 25 years.Discussion
Recent studies have highlighted the necessity of tailored
CRC screening for individuals with cystic ﬁbrosis, reporting
that these individuals have an increased risk of CRC
compared with the average population.5–8 Using an
established micro-simulation model, adjusted for the
Table 2.Efﬁcient Screening Strategies Among Non-Transplant Cystic Fibrosis Patients According to Screening Tests Used
Outcomes per 1,000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($1,000)
Net costs
($1,000)
Reductionsb (%)
ICER
($1,000)FIT COLs
CRC
incidencec
CRC
mortalityc
Colonoscopy strategies
(main analysis)
No screening 0 0 0 23 0 52 19 134 0 1918 0 0 0 –
COL 50–55 y, 10 y 0 214 334 558 3 32 7 127 29 2016 97 38 62 3
COL 50–60 y, 10 y 0 225 345 579 3 31 7 127 30 2021 103 40 66 4
COL 50–60 y, 5 y 0 234 354 597 3 31 6 126 31 2025 107 41 67 9
COL 50–70 y, 5 y 0 235 354 598 3 31 6 126 31 2026 107 41 67 14
COL 45–75 y, 5 y 0 394 531 931 3 27 5 117 38 2222 303 48 74 27
COL 40–70 y, 5 y 0 689 724 1417 4 25 4 109 44 2591 673 52 79 62
COL 40–75 y, 5 y 0 689 724 1417 4 25 4 109 44 2591 673 52 79 84
COL 40–75 y, 3 y 0 793 1301 2097 5 20 3 93 48 3078 1159 63 84 128
COL 35–75 y, 3 y 0 1482 1700 3185 5 18 2 84 53 4000 2082 67 88 174
COL 30–75 y, 3 y 0 2671 2062 4734 6 17 2 77 57 5370 3451 68 90 383
All screening strategies
(supplementary analysis)
No screening 0 0 0 23 0 52 19 134 0 1918 0 0 0 –
COL 50–55 y, 10 y 0 214 334 558 3 32 7 127 29 2016 97 38 62 3
COL 50–60 y, 10 y 0 225 345 579 3 31 7 127 30 2021 103 40 66 4
COL 50–60 y, 5 y 0 234 354 597 3 31 6 126 31 2025 107 41 67 9
COL 50–70 y, 5 y 0 235 354 598 3 31 6 126 31 2026 107 41 67 14
FIT 40–75 y 4125 0 300 519 2 38 5 164 41 2286 368 28 75 25
FIT 35–75 y 6772 0 367 675 2 36 4 163 46 2501 583 31 78 47
FIT 30–75 y 10,783 0 427 872 2 36 4 163 49 2830 912 32 80 103
COL 35–75 y, 3 y 0 1482 1700 3185 5 18 2 84 53 4000 2082 67 88 263
COL 30–75 y, 3 y 0 2671 2062 4734 6 17 2 77 57 5370 3451 68 90 383
COL, colonoscopy; CRC, colorectal cancer; FIT, fecal immunochemical test; LY, life-years; LYG, LY gained compared with no screening; ICER, Incremental cost-
effectiveness ratio (costs/LYs gained).
NOTE. Bold rows indicate optimal screening strategies.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Table 3.Efﬁcient Screening Strategies Among Transplant Cystic Fibrosis Patients According to Screening Tests Used
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at a e 30 years in 2017 (with organ
transplant at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($1,000)
Net costs
($1,000)
Reductionsb (%)
ICER
($1,000)FIT COLs
CRC
incidencec
CRC
mortalityc
Colonoscopy strategies
(main analysis)
No screening 0 0 0 30 0 52 22 115 0 2,065 0 0 0 –
COL 45–55 y, 10 y 0 199 342 553 2 39 9 139 28 2,438 374 25 57 1
COL 45–55 y, 5 y 0 200 343 554 2 39 9 139 28 2,439 374 25 58 7
COL 40–55 y, 5 y 0 324 591 923 3 34 7 129 42 2,601 536 36 70 12
COL 35–55 y, 5 y 0 607 838 1,451 3 31 5 122 52 3,028 963 41 77 45
COL 35–55 y, 3 y 0 642 1,265 1,912 4 26 4 110 56 3,347 1,282 49 82 71
COL 30–55 y, 3 y 0 1,511 1,826 3,340 5 25 3 99 64 4,622 2,558 53 87 166
All screening strategies
(supplementary analysis)
No screening 0 0 0 30 0 52 22 115 0 2,065 0 0 0 –
COL 45–55 y, 10 y 0 199 342 553 2 39 9 139 28 2,438 374 25 57 1
COL 45–55 y, 5 y 0 200 343 554 2 39 9 139 28 2,439 374 25 58 7
COL 40–55 y, 5 y 0 324 591 923 3 34 7 129 42 2,601 536 36 70 12
FIT 35–55 y 3,419 0 377 620 2 42 6 175 48 2,756 691 19 72 27
FIT 30–55 y 6,702 0 460 811 2 41 5 177 54 3,050 985 21 76 47
FIT 30–60 y 6,722 0 463 816 2 41 5 178 54 3,068 1,003 20 77 86
COL 35–55 y, 3 y 0 642 1,265 1,912 4 26 4 110 56 3,347 1,282 49 82 156
COL 30–55 y, 3 y 0 1,511 1,826 3,340 5 25 3 99 64 4,622 2,558 53 87 166
COL, colonoscopy; CRC, colorectal cancer; FIT, fecal immunochemical test; LY, life-years; LYG, LY gained compared w th no screening; ICER, Incremental cost-
effectiveness ratio (costs/LYs gained).
NOTE. Bold rows indicate optimal screening strategies.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Table 4.The Optimal Screening Strategies in Base Case and Sensitivity Analyses for Transplant and Non-transplant Cystic
Fibrosis Individuals
Assumptions
for the sensitivity analyses
Non-transplant
CF patients
Transplant
CF patients
Colonoscopy
(main analysis)
All tests
(supplementary
analysis)
Colonoscopy
(main analysis)
All tests
(supplementary
analysis)
Base case COL
40–75 (5)
FIT
35–75
COL
35–55 (3)
FIT
30–60
Worst-case
sensitivity for colonoscopy test
B B B B
More proximal adenoma location B B B B
Higher rates
of colonoscopy complications
B B B B
Higher rates
of cardiovascular complications
(5-fold increased)
COL
40–70 (5)
B B B
Higher rates
of cardiovascular complications
(10-fold increased)
COL
40–70 (5)
B B B
Worst-case speciﬁcity for FIT (0.90) B B B B
Worst-case for
speciﬁcity (0.75) and sensitivity
(36% reduced) for FIT
B FIT
40–75
B COL
35–55 (3)
Biennial screening intervals for FIT B COL
40–75 (5)
B COL
35–55 (3)
Lower adherence for screening tests B B B B
Intensive surveillance B B B B
Higher patient time costs COL
45–75 (5)
B COL
35–55 (5)
FIT
30–55
Only for no transplant CF patients
Increased CRC risk with more
proximal adenoma location
(10-fold increased risk)
COL
40–75 (3)
FIT
30–75
– –
Shorter adenoma dwelling time
(94% reduced)
COL
40–70 (3)
FIT
30–75
– –
Higher overall mortality in older
ages ( 45 years)
COL
40–55 (5)
FIT
35–60
– –
Only for transplant CF patients
Organ transplant at:
Age 20 – – COL
30–55 (10)
FIT
25–55
Age 25 – – COL
30–55 (5)
FIT
25–55
Additional colonoscopy screening
strategy (every 5 years) starting
at age 32 for transplant patients
(organ transplant at age 30)
– – B B
Increased CRC risk with more
proximal adenoma location (45-
fold increased risk)
– – B COL
35–55 (3)
Age-speciﬁc overall mortality rates of
non-transplant CF after 50 years
– – COL
35–60 (3)
COL
35–60 (3)
Shorter adenoma dwelling time
(50% reduced) with adjusted
CRC risk (16-fold increased)
– – B COL
35–55 (3)
B, optimal strategy is the same of the base case; COL, colonoscopy; FIT, fecal immunochemical test; (n), screening interval;
CF, cystic ﬁbrosis.
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ATcharacteristics of cystic ﬁbrosis populations, we found that
the recommended US CRC screening strategy for the general
population was not optimal for individuals with cystic
ﬁbrosis. A greater reduction in CRC mortality could be
achieved if screening started before age 50 in both in-
dividuals who have and have not received an organ trans-
plantation. Colonoscopy every 5 years starting at age 40 in
individuals with cystic ﬁbrosis who have not received a
transplant was shown, in our study, to signiﬁcantly improve
LYG and CRC mortality at an acceptable cost (ICER of
$84,000 per LYG). Our cost-effectiveness analysis suggests,
for cystic ﬁbrosis patients who underwent organ trans-
plantation, more intensive colonoscopy screening starting at
ages 30 (transplant at age 20 or 25) or 35 (transplant at age
30), through to age 55. The optimal screening interval var-
ied according to age at organ transplant and patient time
costs. The model also suggested that screening with FIT
could be more cost-effective than colonoscopy (Supple-
mentary analysis), but speciﬁc evidence of its performance
in the cystic ﬁbrosis population is required before consid-
ering this screening modality.
Despite the lower life-expectancy reported in cystic
ﬁbrosis population, the model suggests – especially for
those who have not undergone organ transplantation – that
screening should be repeated until age 75 years. Few in-
dividuals with cystic ﬁbrosis currently reach this age, but
once they survive to a certain age (ie, 65–70) their excess
risk of dying compared with the general population be-
comes smaller and a death from CRC becomes more likely.
Thus, screening is effective until age 75. However, the model
was adjusted to reﬂect data on individuals with cystic
ﬁbrosis provided by the ﬁbrosis Foundation Patient Regis-
try, which contains only a very small number of individuals
at older ages. Moreover, a previous study has shown that
some death dates were missing in the ﬁbrosis Foundation
Patient Registry, especially for individuals with cystic
ﬁbrosis older than 45 years, when compared with national
vital statistics.45 Therefore, the model results on the age to
stop screening could be less robust than those obtained on
the age to start screening. A speciﬁc sensitivity analysis,
carried out assuming a higher overall mortality in cystic
ﬁbrosis long-term survivors as reported by Nick et al in
Colorado,45 conﬁrmed this hypothesis (Table 4). This
potentially incomplete ascertainment of outcomes may also
affect estimates for CRC incidence. In that case, we would
have underestimated the risk of CRC and the optimal colo-
noscopy screening strategy would be even more intensive
than the base case: colonoscopy screening should start at
age 40 and repeated every 3 years.
At the same time, our model suggests to screen in-
dividuals with cystic ﬁbrosis who have had an organ
transplant up to age 55. This difference is mainly related to
the higher CRC risk seen in cystic ﬁbrosis individuals after
transplantation. Performing our analysis on transplant
cystic ﬁbrosis individuals (assuming transplant at age 30
years), the model predicted that all these patients developed
1 or more adenomas before age 55 and, therefore, entered
colonoscopy surveillance rather than attending subsequent
screening rounds. As a result, outcomes of similar strategieswith different ages to stop screening, above age 60, were the
same (Supplementary Tables 5–6). Although individuals
with cystic ﬁbrosis had a more frequent adenoma onset
after organ transplant, the increase in CRC incidence was
not as immediate, potentially because of the lag-time in the
progression between adenoma and CRC.46 This was shown
in our analysis for starting screening age in transplant cystic
ﬁbrosis patients that underwent organ transplant at age 30.
Speciﬁc screening recommendations already exist for
several groups of individuals at higher risk of CRC: in-
dividuals with family history of CRC (ﬁrst-degree relative)
are recommended to undergo colonoscopy every 5–10
years, starting at age 40.47 Individuals with Lynch syndrome
should undergo colonoscopy every 1–2 years starting at age
20–25 years.48 CRC risk in the cystic ﬁbrosis population falls
somewhere between the risk of these different groups, with
the risk in transplant patients (30-fold increase compared
with general population)6 being higher than Lynch syn-
drome patients.49 This indicates that individuals with cystic
ﬁbrosis should potentially have similar recommendations as
these other high-risk groups. However, it is also necessary
to consider the different life expectancy of individuals with
cystic ﬁbrosis compared with individuals in other high-risk
groups because this may inﬂuence the balance between the
harms and beneﬁts of screening. This effect may be seen in
Table 1. Although patients with cystic ﬁbrosis have an up to
30-fold increased CRC risk compared with average US in-
dividuals, CRC deaths predicted among them were less than
reported for the US general population (19.1 and 22.3 vs
27.8 per 1000) because of their more elevated ‘other cause’
mortality (70% of the deaths in cystic ﬁbrosis individuals
are related to cardiorespiratory causes).4 While early diag-
nosis may prevent a CRC death, screening may result in an
over-diagnosis because of cystic ﬁbrosis-related competing
causes of death, and can incur in additional costs from
screening and treatment. Thus, CRC screening guidelines for
the other high-risk group cannot be simply generalized to
individuals with cystic ﬁbrosis. This may explain why, unlike
for individuals with Lynch syndrome, more intensive
screening strategies were not found to be cost-effective for
the cystic ﬁbrosis population.
Several studies have recently highlighted the necessity of
tailored CRC screening for the cystic ﬁbrosis population5–8
and, to our knowledge, this is the ﬁrst study to assess the
cost-effectiveness of CRC screening in these individuals. The
results of this formal decision analysis, which was requested
by the Cystic Fibrosis Foundation and cystic Fibrosis
Foundation and Cystic Fibrosis CRC Screening Task Force to
inform the cystic ﬁbrosis CRC screening consensus recom-
mendations19 have provided important suggestions for cli-
nicians, researchers, and policy makers who were tasked
with developing an appropriate CRC screening policy for
people with cystic ﬁbrosis in the US. However, the ﬁndings
of this study should be interpreted with caution considering
the following limitations. First, we did not model the natural
history of CRC separately for men and women. Epidemio-
logical studies among cystic ﬁbrosis patients report gender
differences: women experience a lower risk of developing
CRC6 and lower life-expectancy50 than men. Considering
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could be optimal for women with cystic ﬁbrosis. However,
there is little data on CRC incidence and mortality in these
patients and even less is stratiﬁed by gender, meaning this
differentiation is not yet feasible. Second, our analysis was
not stratiﬁed for pulmonary function (an important clinical
indicator of the health of individuals with cystic ﬁbrosis).
Although Niccum and colleagues8 only considered cystic
ﬁbrosis patients with predicted FEV1  40% eligible to CRC
screening, the available data for individuals with cystic
ﬁbrosis did not permit this additional model stratiﬁcation.
The most recent Cystic Fibrosis Patient Registry Annual
Report showed that up to 75% of individuals with cystic
ﬁbrosis aged 40 years had a predicted FEV1  40%.4 If
screening was limited to this subset of individuals, the
balance between harms and beneﬁts of screening in in-
dividuals with cystic ﬁbrosis would become more favorable.
Furthermore, we assumed that adenomas in persons
with cystic ﬁbrosis could arise following the same
localization-speciﬁc distribution observed in autopsy
studies for the general population24–33 and with the same
increased risk – 7-fold compared with the general popula-
tion – in both the colon and rectum. Although Maisonneuve
and colleagues6 reported that CRC cases were mainly
located in the colon of individuals with cystic ﬁbrosis (26
out 28 cases), a direct calibration of the adenoma
localization-speciﬁc onset distribution was not possible
because limited data is currently available. To address this,
we performed a sensitivity analysis to assess the effects of
assuming a different localization-speciﬁc distribution for
adenoma onset in people with cystic ﬁbrosis and screening
strategy outcomes were not sensitive to this assumption
(Table 4).
Several factors may cause the higher risk of CRC in the
cystic ﬁbrosis population, but information about the ratio-
nale of this increased risk remains unclear. We assumed that
the higher risk of CRC shown in the cystic ﬁbrosis popula-
tion was because of a more frequent adenoma onset. This
assumption was validated for non-transplant patients, but
not for individuals with cystic ﬁbrosis who had an organ
transplant (Supplementary Figure 3). A shorter adenoma
dwell time may also play a role in the progression from
adenoma to CRC. To investigate this, we performed a spe-
ciﬁc sensitivity analysis assuming a shorter dwell time (50%
reduced, faster adenoma progression) and more elevated
adenoma onset (16-fold increased risk) for transplant cystic
ﬁbrosis patients. The results of this sensitivity analysis were
validated with adenoma detection rates observed in an
observational study of cystic ﬁbrosis patients undergoing
colonoscopy screening (Supplementary Figure 3).8 Howev-
er, this analysis revealed that our cost-effectiveness out-
comes were not sensitive to this assumption. Our model
does not explicitly describe adenoma histology and that may
explain the lower simulated rates of colonoscopy-detected
advanced adenomas (Supplementary Figure 3).
In our study, assumptions on colonoscopy performance,
complications, polypectomy safety, costs (including sedation
costs), and adverse events of bowel preparation were
informed by data from the general population and theMedicare population40 because speciﬁc empirical data for
the cystic ﬁbrosis population were not available. For colo-
noscopy performance, this assumption seems reasonable
because model-predicted adenoma detection rates were
close to observed (Supplementary Figure 3). However, it
may be reasonable to assume that risk of complications
and/or inadequate bowel preparation is higher in people
with cystic ﬁbrosis compared with the general population.
Also, the more intensive and extended bowel preparation
regimens for individuals with cystic ﬁbrosis and additional
colonoscopy investigations because of inadequate bowel
preparation could lead to a further increase in adverse
events. To address this concern, we performed speciﬁc
sensitivity analyses on colonoscopy performance and rate of
complications (especially for cardiovascular adverse events,
including respiratory arrest, Supplementary Tables 7 and 8).
Results of these analyses showed that the optimal screening
starting ages and intervals were not sensitive to changes in
these assumptions (Table 4).
The feasibility of colonoscopy in individuals with cystic
ﬁbrosis and its capacity to early detect CRC and adenomas
in these individuals was suggested by the ﬁndings of a small
observational study conducted in Minnesota.8 Moreover,
colonoscopy is the screening test of choice for higher-risk
groups.47,48 We therefore focused our main analysis and
interpretation of our results on this screening modality.
However, given the potential burden of colonoscopy and
colonoscopy preparation to the cystic ﬁbrosis patient, we
believe it was pertinent to also consider FIT as a possible
and hypothetically adequate alternative. As such, we per-
formed a speciﬁc supplementary analysis including annual
FIT screening. We found that this screening modality was
cost-effective and optimal among individuals with cystic
ﬁbrosis. However, because information on FIT characteris-
tics in this population is lacking, the analysis was performed
using FIT characteristics from the general population.37
In individuals with cystic ﬁbrosis, the presence of blood
in feces could be related to several gastrointestinal
disorders,51 which could affect the effectiveness and
cost-effectiveness of FIT screening in the cystic ﬁbrosis pop-
ulation. Sensitivity analyses revealed that our results on
cost-effectiveness of FIT depend on screening intensity and
the test characteristics as assumed in this analysis, especially
for post-transplant cystic ﬁbrosis patients. Hence, before
considering FIT as the preferred screening modality, FIT
performance must be tested in the cystic ﬁbrosis population
to better explore its effectiveness in early detection of CRC
and adenomas among this population. If future studies
conﬁrm that FIT in individuals with cystic ﬁbrosis performs
as well as or better than we assumed in our sensitivity
analyses, FIT may be considered an attractive screening
option for this population. In the meantime, FIT could be
considered for those not willing to undergo colonoscopy.
Despite its limitations, this study has important clinical
and policy implications. This study indicates that there is
beneﬁt to earlier CRC screening in the cystic ﬁbrosis pop-
ulation and can be done at acceptable costs. The ﬁndings of
this analysis support clinicians, researchers, and policy
makers who aim to deﬁne a tailored CRC screening for
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comes of screening in individuals with cystic ﬁbrosis should
be closely monitored to accumulate evidence on the per-
formance and safety of CRC screening in these individuals.
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Supplementary Table 1.Test Characteristics of Colonoscopy and Fecal Immunochemical Tests (FIT)
Test Characteristic
Tests
Colonoscopya FITb
Speciﬁcity, % 0.86c 0.964
Sensitivity, %
Small adenomas (5 mm) 0.75 0.076d
Medium adenomas (6–9 mm) 0.85 0.076d
Large adenomas (10 mm) 0.95 0.238e
CRCs that would not have been
clinically detected in their
current stage
0.95 0.625f
CRCs that would have been
clinically detected in their
current stage
0.95 0.886f
Reach 95% reaches the cecum; the reach
of the remaining 5% is distributed uniformly
over colon and rectum
Whole
colon and rectum
Complication rate Increases exponentially with ageg 0
Mortality rate 0.0000191h 0
aThe sensitivity of colonoscopy for the detection of adenomas and CRC within the reach of the endoscope was obtained from
a systematic review on miss rates seen in tandem colonoscopy studies.33
bFIT characteristics were based on a large US-based study comparing multi-targeted stool DNA with FIT in a screening
setting.34
cSpeciﬁcity for colonoscopy is therefore based on an adenoma prevalence study of patients undergoing screening
colonoscopy.36
dSensitivity for non-advanced adenomas (not reported separately for medium adenomas).
eSensitivity for advanced adenomas (not reported for large adenomas).
fThese estimates were found by calibrating our model outcomes to the per-person sensitivities given in the multi-targeted stool
DNA with FIT.34
gAge-speciﬁc risks for complications of colonoscopy requiring a hospital admission or emergency department visit were
obtained from a study by Warren et al.37
hThe mortality rate associated with colonoscopies with a polypectomy was derived by multiplying the risk for a perforation
obtained from a study by Warren et al37 by the risk for death given a perforation obtained from a study by Gatto et al.35
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Supplementary Table 2.Costs Associated With Colorectal Cancer Screening in the Base Case and Cost Sensitivity Analysis
Costs, $a
Higher costs for colonoscopy, $
(sensitivity analysis)e
Per FIT 40 –
Per colonoscopy
Without polypectomy/biopsy 880 1400
With polypectomy/biopsy 1200 1700
Per complication of colonoscopy
Seriousb GI complications 8100 11,200
Otherc GI complications 6200 7600
Cardiovascular complicationsd 6700 8500
Per LY with CRC care
Initial care
Stage I CRC 36,900 –
Stage II CRC 49,500 –
Stage III CRC 60,100 –
Stage IV CRC 78,200 –
Continuing care
Stage I CRC 3100 –
Stage II CRC 2900 –
Stage III CRC 4100 –
Stage IV CRC 12,300 –
Terminal Care, ending in CRC death
Stage I CRC 64,200 –
Stage II CRC 63,900 –
Stage III CRC 67,400 –
Stage IV CRC 88,900 –
Terminal Care, ending in other-cause death
Stage I CRC 19,400 –
Stage II CRC 17,400 –
Stage III CRC 21,600 –
Stage IV CRC 50,200 –
GI, gastrointestinal; FIT, fecal immunochemical test.
aCosts are presented in 2015 US dollars and include co-payments and patient time costs (ie, the opportunity costs of spending
time on screening or being treated for a complication or CRC) but do not include travel costs, costs of lost productivity, and
unrelated health care and non–health care costs in added years of life. We assumed that the value of patient time was equal to
the median wage rate in 2014: $17.01/hour. Cost values were estimated for the year 2014. We assumed that FITs, colo-
noscopies, and complications used up 1, 8, and 16 hours of patient time, respectively. Patient time costs were already
included in the estimates for the costs of LYs with CRC care obtained from a study by Yabroff et al.40 All costs were adjusted
for the year 2015 using the annual average Consumer Price Indexes provided by US Bureau of Labor Statistics.41
bSerious GI complications included perforations, gastrointestinal bleeding, or transfusions.
cOther GI complications included paralytic ileus, nausea and vomiting, dehydration, or abdominal pain.
dCardiovascular complications included myocardial infarction or angina, arrhythmias, congestive heart failure, cardiac or
respiratory arrest, syncope, hypotension, or shock.
eWe assumed that colonoscopies and complications used up 40 and 190 hours of patient time, respectively.
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Supplementary Table 3.Outcomes With Colonoscopy Screening Strategies that Vary by the Ages to Begin and End Screening Among Non-transplant Cystic Fibrosis
Patients
Outcomes per 1000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
No screening 0 0 0 23 0 52 19 134 0 1,918,503 0 0 0 Dominated
COL 50–55 y
3 y 0 234 566 808 4 28 6 119 32 2,148,408 229,905 47 70 Dominated
5 y 0 231 352 591 3 31 6 126 31 2,023,494 104,991 41 66 Dominated
10 y 0 214 334 558 3 32 7 127 29 2,015,966 97,463 38 62 Efﬁcient
COL 50–60 y
3 y 0 242 575 825 4 27 6 119 33 2,155,878 237,376 48 71 Dominated
5 y 0 234 354 597 3 31 6 126 31 2,025,210 106,707 41 67 Efﬁcient
10 y 0 225 345 579 3 31 7 127 30 2,021,207 102,704 40 66 Efﬁcient
COL 50–65 y
3 y 0 244 576 827 4 27 6 119 33 2,157,230 238,727 48 71 Dominated
5 y 0 235 354 598 3 31 6 126 31 2,025,651 107,148 41 67 Dominated
10 y 0 225 345 579 3 31 7 127 30 2,021,207 102,704 40 66 Dominated
COL 50–70 y
3 y 0 244 576 828 4 27 6 119 33 2,157,394 238,892 48 71 Dominated
5 y 0 235 354 598 3 31 6 126 31 2,025,716 107,213 41 67 Efﬁcient
10 y 0 226 346 580 3 31 6 127 30 2,021,651 103,148 40 66 Dominated
COL 50–75 y
3 y 0 244 576 828 4 27 6 119 33 2,157,431 238,928 48 71 Dominated
5 y 0 235 354 598 3 31 6 126 31 2,025,729 107,227 41 67 Dominated
10 y 0 226 346 580 3 31 6 127 30 2,021,651 103,148 40 66 Dominated
COL 45–55 y
3 y 0 419 896 1320 4 23 4 105 41 2,475,197 556,694 56 78 Dominated
5 y 0 390 528 925 3 28 5 117 38 2,219,433 300,930 47 73 Dominated
10 y 0 361 505 873 3 28 5 119 37 2,195,135 276,632 46 72 Dominated
COL 45–60 y
3 y 0 424 901 1331 4 23 4 105 41 2,479,908 561,406 56 79 Dominated
5 y 0 393 530 930 3 27 5 117 38 2,221,064 302,561 48 74 Dominated
10 y 0 361 505 873 3 28 5 119 37 2,195,135 276,632 46 72 Dominated
COL 45–65 y
3 y 0 425 902 1332 4 23 4 105 41 2,480,593 562,090 56 79 Dominated
5 y 0 394 531 931 3 27 5 117 38 2,221,496 302,994 48 74 Dominated
10 y 0 364 507 877 3 28 5 119 37 2,197,099 278,597 46 73 Dominated
COL 45–70 y
3 y 0 426 902 1333 4 23 4 105 41 2,480,935 562,432 57 79 Dominated
5 y 0 394 531 931 3 27 5 117 38 2,221,588 303,085 48 74 Dominated
10 y 0 364 507 877 3 28 5 119 37 2,197,099 278,597 46 73 Dominated
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Supplementary Table 3.Continued
Outcomes per 1000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
COL 45–75 y
3 y 0 426 902 1333 4 23 4 105 41 2,480,965 562,462 57 79 Dominated
5 y 0 394 531 931 3 27 5 117 38 2,221,593 303,090 48 74 Efﬁcient
10 y 0 364 507 877 3 28 5 119 37 2,197,180 278,677 46 73 Dominated
COL 40–55 y
3 y 0 788 1297 2088 5 20 3 93 48 3,073,485 1,154,982 62 84 Dominated
5 y 0 685 721 1411 4 25 4 109 44 2,589,046 670,543 52 78 Dominated
10 y 0 584 654 1243 4 27 5 113 41 2,486,943 568,440 48 73 Dominated
COL 40–60 y
3 y 0 791 1300 2094 5 20 3 93 48 3,075,938 1,157,436 63 84 Dominated
5 y 0 688 723 1416 4 25 4 109 44 2,590,515 672,012 52 79 Dominated
10 y 0 592 663 1261 4 27 5 114 42 2,491,257 572,754 49 76 Dominated
COL 40–65 y
3 y 0 793 1301 2097 5 20 3 93 48 3,077,629 1,159,127 63 84 Dominated
5 y 0 689 724 1417 4 25 4 109 44 2,590,952 672,449 52 79 Dominated
10 y 0 592 663 1261 4 27 5 114 42 2,491,257 572,754 49 76 Dominated
COL 40–70 y
3 y 0 793 1301 2097 5 20 3 93 48 3,077,867 1,159,364 63 84 Dominated
5 y 0 689 724 1417 4 25 4 109 44 2,591,030 672,527 52 79 Efﬁcient
10 y 0 593 663 1261 4 27 4 114 42 2,491,646 573,143 49 77 Dominated
COL 40–75 y
3 y 0 793 1301 2097 5 20 3 93 48 3,077,874 1,159,371 63 84 Efﬁcient
5 y 0 689 724 1417 4 25 4 109 44 2,591,048 672,546 52 79 Optimal
10 y 0 593 663 1261 4 27 4 114 42 2,491,646 573,143 49 77 Dominated
COL 35–55 y
3 y 0 1473 1691 3167 5 18 2 85 53 3,992,038 2,073,535 66 87 Dominated
5 y 0 1194 907 2105 4 24 4 104 48 3,174,604 1,256,101 54 81 Dominated
10 y 0 939 802 1745 4 26 4 110 45 2,900,743 982,240 51 78 Dominated
COL 35–60 y
3 y 0 1481 1699 3182 5 18 2 84 53 3,998,695 2,080,192 66 88 Dominated
5 y 0 1197 909 2110 4 24 4 104 48 3,175,886 1,257,384 55 81 Dominated
10 y 0 939 802 1745 4 26 4 110 45 2,900,743 982,240 51 78 Dominated
COL 35–65 y
3 y 0 1482 1700 3185 5 18 2 84 53 4,000,132 2,081,629 67 88 Dominated
5 y 0 1198 909 2111 4 24 4 104 48 3,176,328 1,257,825 55 82 Dominated
10 y 0 941 803 1749 4 25 4 110 45 2,902,724 984,222 51 79 Dominated
COL 35–70 y
3 y 0 1482 1700 3185 5 18 2 84 53 4,000,269 2,081,766 67 88 Dominated
5 y 0 1198 909 2111 4 24 4 104 48 3,176,413 1,257,910 55 82 Dominated
10 y 0 941 803 1749 4 25 4 110 45 2,902,724 984,222 51 79 Dominated
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Supplementary Table 3.Continued
Outcomes per 1000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
COL 35–75 y
3 y 0 1482 1700 3185 5 18 2 84 53 4,000,326 2,081,823 67 88 Efﬁcient
5 y 0 1198 909 2111 4 24 4 104 48 3,176,422 1,257,919 55 82 Dominated
10 y 0 942 803 1749 4 25 4 110 45 2,902,790 984,287 51 79 Dominated
COL 30–55 y
3 y 0 2664 2056 4722 6 17 2 78 56 5,363,829 3,445,326 68 89 Dominated
5 y 0 2019 1081 3103 4 23 3 99 51 4,054,185 2,135,683 56 83 Dominated
10 y 0 1469 930 2404 4 26 4 107 47 3,490,661 1,572,158 51 77 Dominated
COL 30–60 y
3 y 0 2670 2061 4733 6 17 2 77 57 5,368,594 3,450,091 68 90 Dominated
5 y 0 2022 1083 3108 4 23 3 99 52 4,055,530 2,137,027 56 83 Dominated
10 y 0 1478 939 2421 4 25 4 107 48 3,494,835 1,576,333 53 80 Dominated
COL 30–65 y
3 y 0 2670 2062 4734 6 17 2 77 57 5,369,313 3,450,810 68 90 Dominated
5 y 0 2022 1084 3109 4 23 3 99 52 4,056,006 2,137,503 56 83 Dominated
10 y 0 1478 939 2421 4 25 4 107 48 3,494,835 1,576,333 53 80 Dominated
COL 30–70 y
3 y 0 2671 2062 4734 6 17 2 77 57 5,369,646 3,451,143 68 90 Dominated
5 y 0 2022 1084 3109 4 23 3 99 52 4,056,097 2,137,594 56 83 Dominated
10 y 0 1479 939 2422 4 25 4 107 48 3,495,178 1,576,675 53 80 Dominated
COL 30–75 y
3 y 0 2671 2062 4734 6 17 2 77 57 5,369,680 3,451,178 68 90 Efﬁcient
5 y 0 2022 1084 3109 4 23 3 99 52 4,056,118 2,137,616 56 83 Dominated
10 y 0 1479 939 2422 4 25 4 107 48 3,495,178 1,576,675 53 80 Dominated
COL, colonoscopy; CRC, colorectal cancer; LY, life-years; LYG, LY gained compared with no screening; Grey row indicates optimal screening strategy.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Supplementary Table 4.Outcomes With FIT Screening Strategies that Vary by the Ages to Begin and End Screening Among Non-transplant Cystic Fibrosis Patients
Outcomes per 1,000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
No screening 0 23 0 23 0 52 19 134 0 1,918,503 0 0 0 Dominated
FIT 50–55 y 864 0 120 210 1 45 12 153 19 2,038,443 119,940 13 37 Dominated
FIT 50–60 y 1164 0 148 255 1 43 9 158 25 2,052,169 133,666 18 50 Dominated
FIT 50–65 y 1300 0 158 273 2 42 8 161 27 2,063,754 145,251 20 58 Dominated
FIT 50–70 y 1353 0 161 279 2 42 7 163 28 2,072,133 153,630 20 61 Dominated
FIT 50–75 y 1369 0 162 281 2 42 7 163 28 2,074,725 156,222 20 62 Dominated
FIT 45–55 y 1959 0 194 329 2 42 10 155 28 2,115,102 196,599 19 48 Dominated
FIT 45–60 y 2228 0 216 366 2 40 8 159 32 2,126,869 208,366 23 59 Dominated
FIT 45–65 y 2352 0 226 382 2 40 7 162 34 2,137,804 219,302 25 65 Dominated
FIT 45–70 y 2400 0 228 388 2 39 6 163 35 2,145,442 226,939 25 69 Dominated
FIT 45–75 y 2416 0 229 389 2 39 6 164 35 2,148,080 229,577 25 70 Dominated
FIT 40–55 y 3696 0 268 463 2 40 9 155 34 2,252,661 334,158 23 54 Dominated
FIT 40–60 y 3948 0 288 497 2 39 7 159 38 2,266,287 347,784 27 64 Dominated
FIT 40–65 y 4064 0 296 512 2 38 6 162 40 2,276,322 357,819 28 70 Dominated
FIT 40–70 y 4110 0 299 517 2 38 5 163 41 2,283,302 364,799 28 73 Dominated
FIT 40–75 y 4125 0 300 519 2 38 5 164 41 2,286,016 367,513 28 75 Efﬁcient
FIT 35–55 y 6360 0 336 622 2 39 8 155 39 2,469,942 551,440 26 58 Dominated
FIT 35–60 y 6602 0 356 654 2 37 6 159 43 2,482,622 564,119 29 68 Dominated
FIT 35–65 y 6714 0 364 668 2 36 5 162 45 2,492,455 573,952 30 74 Dominated
FIT 35–70 y 6758 0 366 674 2 36 4 163 45 2,498,628 580,125 31 77 Dominated
FIT 35–75 y 6772 0 367 675 2 36 4 163 46 2,501,004 582,501 31 78 Optimal
FIT 30–55 y 10,379 0 397 821 2 38 8 155 42 2,800,037 881,534 27 61 Dominated
FIT 30–60 y 10,616 0 416 852 2 36 6 159 46 2,812,063 893,560 30 70 Dominated
FIT 30–65 y 10,726 0 424 866 2 36 5 161 48 2,821,545 903,042 32 76 Dominated
FIT 30–70 y 10,769 0 427 871 2 36 4 162 49 2,828,060 909,557 32 78 Dominated
FIT 30–75 y 10,783 0 427 872 2 36 4 163 49 2,830,319 911,816 32 80 Efﬁcient
COL, colonoscopy; CRC, colorectal cancer; LY, life-years; LYG, LY gained compared with no screening; FIT, fecal immunochemical test; Grey row indicates optimal
screening strategy.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Supplementary Table 5.Outcomes With Colonoscopy Screening Strategies that Vary by the Ages to Begin and End Screening Among Transplant Cystic Fibrosis Patients
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant
at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
No screening 0 0 0 30 0 52 22 115 0 2,064,654 0 0 0 Dominated
COL 50–55 y
3 y 0 125 173 314 2 48 13 143 15 2,437,339 372,685 8 40 Dominated
5 y 0 125 152 293 1 48 14 143 14 2,420,864 356,209 8 39 Dominated
10 y 0 124 151 293 1 48 14 143 14 2,419,742 355,087 8 39 Dominated
COL 50–60 y
3 y 0 125 173 314 2 48 13 143 15 2,437,341 372,687 8 40 Dominated
5 y 0 125 152 293 1 48 14 143 14 2,420,865 356,211 8 39 Dominated
10 y 0 124 151 293 1 48 14 143 14 2,420,644 355,990 8 39 Dominated
COL 50–65 y
3 y 0 125 173 314 2 48 13 143 15 2,437,341 372,687 8 40 Dominated
5 y 0 125 152 293 1 48 14 143 14 2,420,865 356,211 8 39 Dominated
10 y 0 124 151 293 1 48 14 143 14 2,420,644 355,990 8 39 Dominated
COL 50–70 y
3 y 0 125 173 314 2 48 13 143 15 2,437,341 372,687 8 40 Dominated
5 y 0 125 152 293 1 48 14 143 14 2,420,865 356,211 8 39 Dominated
10 y 0 124 151 293 1 48 14 143 14 2,420,644 355,990 8 39 Dominated
COL 50–75 y
3 y 0 125 173 314 2 48 13 143 15 2,437,341 372,687 8 40 Dominated
5 y 0 125 152 293 1 48 14 143 14 2,420,865 356,211 8 39 Dominated
10 y 0 124 151 293 1 48 14 143 14 2,420,644 355,990 8 39 Dominated
COL 45–55 y
3 y 0 200 416 628 3 38 9 137 29 2,481,276 416,622 27 59 Dominated
5 y 0 200 343 554 2 39 9 139 28 2,438,899 374,244 25 58 Efﬁcient
10 y 0 199 342 553 2 39 9 139 28 2,438,362 373,707 25 57 Efﬁcient
COL 45–60 y
3 y 0 200 416 628 3 38 9 137 29 2,481,280 416,625 27 59 Dominated
5 y 0 200 343 554 2 39 9 139 28 2,438,902 374,247 25 58 Dominated
10 y 0 199 342 553 2 39 9 139 28 2,438,362 373,707 25 57 Dominated
COL 45–65 y
3 y 0 200 416 628 3 38 9 137 29 2,481,280 416,625 27 59 Dominated
5 y 0 200 343 554 2 39 9 139 28 2,438,902 374,247 25 58 Dominated
10 y 0 199 342 553 2 39 9 139 28 2,438,362 373,707 25 57 Dominated
COL 45–70 y
3 y 0 200 416 628 3 38 9 137 29 2,481,280 416,625 27 59 Dominated
5 y 0 200 343 554 2 39 9 139 28 2,438,902 374,247 25 58 Dominated
10 y 0 199 342 553 2 39 9 139 28 2,438,362 373,707 25 57 Dominated
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Supplementary Table 5.Continued
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant
at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
COL 45–75 y
3 y 0 200 416 628 3 38 9 137 29 2,481,280 416,625 27 59 Dominated
5 y 0 200 343 554 2 39 9 139 28 2,438,902 374,247 25 58 Dominated
10 y 0 199 342 553 2 39 9 139 28 2,438,362 373,707 25 57 Dominated
COL 40–55 y
3 y 0 328 774 1109 3 30 6 123 44 2,707,578 642,923 42 74 Dominated
5 y 0 324 591 923 3 34 7 129 42 2,600,975 536,321 36 70 Efﬁcient
10 y 0 320 582 909 3 34 7 129 42 2,597,514 532,860 35 70 Dominated
COL 40–60 y
3 y 0 328 774 1109 3 30 6 123 44 2,707,578 642,924 42 74 Dominated
5 y 0 324 591 923 3 34 7 129 42 2,600,975 536,321 36 70 Dominated
10 y 0 320 582 909 3 34 7 129 42 2,597,584 532,929 35 70 Dominated
COL 40–65 y
3 y 0 328 774 1109 3 30 6 123 44 2,707,578 642,924 42 74 Dominated
5 y 0 324 591 923 3 34 7 129 42 2,600,975 536,321 36 70 Dominated
10 y 0 320 582 909 3 34 7 129 42 2,597,584 532,929 35 70 Dominated
COL 40–70 y
3 y 0 328 774 1109 3 30 6 123 44 2,707,578 642,924 42 74 Dominated
5 y 0 324 591 923 3 34 7 129 42 2,600,975 536,321 36 70 Dominated
10 y 0 320 582 909 3 34 7 129 42 2,597,584 532,929 35 70 Dominated
COL 40–75 y
3 y 0 328 774 1109 3 30 6 123 44 2,707,578 642,924 42 74 Dominated
5 y 0 324 591 923 3 34 7 129 42 2,600,975 536,321 36 70 Dominated
10 y 0 320 582 909 3 34 7 129 42 2,597,584 532,929 35 70 Dominated
COL 35–55 y
3 y 0 642 1265 1912 4 26 4 110 56 3,346,546 1,281,892 49 82 Optimal
5 y 0 607 838 1451 3 31 5 122 52 3,028,100 963,446 41 77 Efﬁcient
10 y 0 571 788 1364 3 32 6 125 49 2,980,739 916,084 39 75 Dominated
COL 35–60 y ,
3 y 0 642 1265 1912 4 26 4 110 56 3,346,548 1,281,894 49 82 Dominated
5 y 0 607 838 1451 3 31 5 122 52 3,028,100 963,446 41 77 Dominated
10 y 0 571 788 1364 3 32 6 125 49 2,980,739 916,084 39 75 Dominated
COL 35–65 y
3 y 0 642 1265 1912 4 26 4 110 56 3,346,548 1,281,894 49 82 Dominated
5 y 0 607 838 1451 3 31 5 122 52 3,028,100 963,446 41 77 Dominated
10 y 0 571 788 1364 3 32 6 125 49 2,980,739 916,084 39 75 Dominated
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Supplementary Table 5.Continued
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant
at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
COL 35–70 y
3 y 0 642 1265 1912 4 26 4 110 56 3,346,548 1,281,894 49 82 Dominated
5 y 0 607 838 1451 3 31 5 122 52 3,028,100 963,446 41 77 Dominated
10 y 0 571 788 1364 3 32 6 125 49 2,980,739 916,084 39 75 Dominated
COL 35–75 y
3 y 0 642 1265 1912 4 26 4 110 56 3,346,548 1,281,894 49 82 Dominated
5 y 0 607 838 1451 3 31 5 122 52 3,028,100 963,446 41 77 Dominated
10 y 0 571 788 1364 3 32 6 125 49 2,980,739 916,084 39 75 Dominated
COL 30–55 y
3 y 0 1511 1826 3340 5 25 3 99 64 4,622,190 2,557,535 53 87 Efﬁcient
5 y 0 1316 1080 2400 4 29 4 117 57 3,888,961 1,824,306 43 80 Dominated
10 y 0 1134 971 2110 4 31 5 121 54 3,656,737 1,592,083 41 77 Dominated
COL 30–60 y
3 y 0 1511 1826 3340 5 25 3 99 64 4,622,193 2,557,539 53 87 Dominated
5 y 0 1316 1080 2400 4 29 4 117 57 3,888,964 1,824,309 43 80 Dominated
10 y 0 1134 971 2110 4 31 5 121 54 3,656,827 1,592,172 41 78 Dominated
COL 30–65 y
3 y 0 1511 1826 3340 5 25 3 99 64 4,622,193 2,557,539 53 87 Dominated
5 y 0 1316 1080 2400 4 29 4 117 57 3,888,964 1,824,309 43 80 Dominated
10 y 0 1134 971 2110 4 31 5 121 54 3,656,827 1,592,172 41 78 Dominated
COL 30–70 y
3 y 0 1511 1826 3340 5 25 3 99 64 4,622,193 2,557,539 53 87 Dominated
5 y 0 1316 1080 2400 4 29 4 117 57 3,888,964 1,824,309 43 80 Dominated
10 y 0 1134 971 2110 4 31 5 121 54 3,656,827 1,592,172 41 78 Dominated
COL 30–75 y
3 y 0 1511 1826 3340 5 25 3 99 64 4,622,193 2,557,539 53 87 Dominated
5 y 0 1316 1080 2400 4 29 4 117 57 3,888,964 1,824,309 43 80 Dominated
10 y 0 1134 971 2110 4 31 5 121 54 3,656,827 1,592,172 41 78 Dominated
COL, colonoscopy; CRC, colorectal cancer; LY, life-years; LYG, LY gained compared with no screening; Grey row indicates optimal screening strategy.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Supplementary Table 6.Outcomes With FIT Screening Strategies that Vary by the Ages to Begin and End Screening Among Transplant Cystic Fibrosis patients
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (with organ transplant
at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
Efﬁcient
strategyFIT COLs
CRC
incidencec
CRC
mortalityc
No screening 0 0 0 30 0 52 22 115 0 2,064,654 0 0 0 Dominated
FIT 50–55 y 327 0 88 189 1 54 15 153 13 2,467,521 402,866 -3 35 Dominated
FIT 50–60 y 360 0 92 198 1 54 14 155 13 2,496,400 431,746 -4 36 Dominated
FIT 50–65 y 364 0 92 199 1 54 14 156 13 2,501,575 436,920 -4 37 Dominated
FIT 50–70 y 364 0 92 199 1 54 14 156 13 2,501,575 436,920 -4 37 Dominated
FIT 50–75 y 364 0 92 199 1 54 14 156 13 2,501,575 436,920 -4 37 Dominated
FIT 45–55 y 813 0 181 322 1 48 11 165 25 2,517,648 452,994 8 53 Dominated
FIT 45–60 y 840 0 184 329 1 48 10 167 26 2,541,004 476,350 7 54 Dominated
FIT 45–65 y 843 0 184 329 1 49 10 167 26 2,545,324 480,670 7 54 Dominated
FIT 45–70 y 843 0 184 329 1 49 10 167 26 2,545,324 480,670 7 54 Dominated
FIT 45–75 y 843 0 184 329 1 49 10 167 26 2,545,324 480,670 7 54 Dominated
FIT 40–55 y 1722 0 283 466 2 44 8 172 38 2,589,414 524,759 15 65 Dominated
FIT 40–60 y 1745 0 286 472 2 45 8 173 38 2,610,117 545,463 14 66 Dominated
FIT 40–65 y 1748 0 286 473 2 45 8 173 38 2,614,004 549,350 14 66 Dominated
FIT 40–70 y 1748 0 286 473 2 45 8 173 38 2,614,004 549,350 14 66 Dominated
FIT 40–75 y 1748 0 286 473 2 45 8 173 38 2,614,004 549,350 14 66 Dominated
FIT 35–55 y 3419 0 377 620 2 42 6 175 48 2,755,648 690,993 19 72 Efﬁcient
FIT 35–60 y 3440 0 380 625 2 42 6 177 48 2,774,500 709,845 18 73 Dominated
FIT 35–65 y 3443 0 380 626 2 43 6 177 48 2,778,104 713,449 18 73 Dominated
FIT 35–70 y 3443 0 380 626 2 43 6 177 48 2,778,104 713,449 18 73 Dominated
FIT 35–75 y 3443 0 380 626 2 43 6 177 48 2,778,104 713,449 18 73 Dominated
FIT 30–55 y 6702 0 460 811 2 41 5 177 54 3,049,935 985,281 21 76 Efﬁcient
FIT 30–60 y 6722 0 463 816 2 41 5 178 54 3,067,680 1,003,026 20 77 Optimal
FIT 30–65 y 6725 0 463 816 2 42 5 178 54 3,071,052 1,006,398 20 77 Dominated
FIT 30–70 y 6725 0 463 816 2 42 5 178 54 3,071,052 1,006,398 20 77 Dominated
FIT 30–75 y 6725 0 463 816 2 42 5 178 54 3,071,052 1,006,398 20 77 Dominated
COL, colonoscopy; CRC, colorectal cancer; LY, life-years; LYG, LY gained compared with no screening; FIT, fecal immunochemical test; Grey row indicates optimal
screening strategy.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Supplementary Table 7.Efﬁcient Colonoscopy Screening Strategies Among Non-transplant Cystic Fibrosis Patients (Assuming 5-fold and 10-fold Increased Rates of
Cardiovascular Complications)
Outcomes per 1,000 non-transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017 (3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
ICER
($1,000)FIT COLs
CRC
incidencec
CRC
mortalityc
Colonoscopy strategies
(5-fold increased rates of
cardiovascular complications)
No screening 0 0 0 23 0 52 19 134 0 1,919,770 0 0 0 –
COL 50–55 y, 10 y 0 214 334 558 5 32 7 127 29 2,034,143 114,374 38 62 4
COL 50–60 y, 10 y 0 225 345 579 6 31 7 127 30 2,040,522 120,753 40 66 5
COL 50–55 y, 5 y 0 231 352 591 6 31 7 126 30 2,042,926 123,156 41 66 10
COL 50–60 y, 5 y 0 234 354 597 6 31 6 126 31 2,044,880 125,111 41 66 10
COL 50–70 y, 5 y 0 235 354 598 6 31 6 126 31 2,045,449 125,679 41 67 16
COL 45–75 y, 5 y 0 394 531 931 7 27 5 117 38 2,244,517 324,748 48 74 28
COL 40–70 y, 5 y 0 689 724 1417 8 25 4 109 44 2,616,434 696,665 52 78 64
COL 40–75 y, 5 y 0 689 724 1417 8 25 4 109 44 2,616,456 696,686 52 78 101
COL 40–75 y, 3 y 0 793 1301 2097 10 20 3 93 47 3,110,299 1,190,530 63 84 137
COL 35–75 y, 3 y 0 1482 1700 3185 11 18 2 84 52 4,035,494 2,115,724 67 87 191
COL 30–75 y, 3 y 0 2671 2062 4734 11 17 2 77 55 5,405,835 3,486,065 68 89 453
Colonoscopy strategies
(10-fold increased rates of
cardiovascular complications)
No screening 0 0 0 23 1 52 19 134 0 1,921,353 0 0 0 –
COL 50–55 y, 10 y 0 214 334 558 9 32 7 127 29 2,056,855 135,502 38 62 5
COL 50–60 y, 10 y 0 225 345 579 9 31 7 127 30 2,064,656 143,303 40 65 7
COL 50–55 y, 5 y 0 231 352 591 9 31 7 126 30 2,067,209 145,856 41 66 10
COL 50–60 y, 5 y 0 234 354 597 10 31 6 126 30 2,069,459 148,106 41 66 11
COL 50–70 y, 5 y 0 235 354 598 10 31 6 126 30 2,070,110 148,756 41 66 19
COL 45–75 y, 5 y 0 394 531 931 11 27 5 117 37 2,273,139 351,786 48 73 29
COL 40–70 y, 5 y 0 689 724 1417 13 25 4 109 43 2,648,184 726,831 52 78 68
COL 40–75 y, 3 y 0 793 1301 2097 16 20 3 93 46 3,150,810 1,229,457 63 83 151
COL 35–75 y, 5 y 0 1198 909 2110 13 24 4 103 47 3,237,207 1,315,854 55 80 209
COL 35–75 y, 3 y 0 1482 1700 3184 17 18 3 84 51 4,079,400 2,158,046 67 86 217
COL 30–75 y, 3 y 0 2670 2061 4733 18 17 2 77 53 5,450,861 3,529,508 68 87 636
COL, colonoscopy; CRC, colorectal cancer; FIT, fecal; LY, life-years; LYG, LY gained compared with no screening; ICER, Incremental cost-effectiveness ratio
(costs/LYs gained).
NOTE. Bold rows indicate optimal screening strategies.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Supplementary Table 8.Efﬁcient Colonoscopy Screening Strategies Among Transplant Cystic Fibrosis Patients (Assuming 5-fold and 10-fold Increased Rates of
Cardiovascular Complications)
Outcomes per 1,000 transplant cystic ﬁbrosis individuals free of diagnosed cancer at age 30 years in 2017
(with organ transplant at age 30, 3% discounted)
Screening tests
Surveillance
COLs
Total
COLs Complications
CRC
casesc
CRC
deatha,c
LY with
CRC LYGb
Total costs
($)
Net costs
($)
Reductionsb (%)
ICER
($1,000)FIT COLs
CRC
incidencec
CRC
mortalityc
Colonoscopy strategies
(5-fold increased rates of
cardiovascular complications)
No screening 0 0 0 30 0 52 22 115 0 2,065,435 0 0 0 –
COL 45–55 y, 10 y 0 199 342 553 4 39 10 139 28 2,452,010 386,576 25 57 2
COL 45–55 y, 5 y 0 200 343 554 4 39 9 139 28 2,452,589 387,154 25 57 8
COL 40–55 y, 5 y 0 324 591 923 6 34 7 129 42 2,618,834 553,399 36 70 12
COL 35–55 y, 5 y 0 607 838 1451 7 31 5 122 51 3,049,189 983,754 41 77 46
COL 35–55 y, 3 y 0 642 1265 1912 8 26 4 110 56 3,373,257 1,307,822 49 82 75
COL 30–55 y, 3 y 0 1511 1825 3339 10 25 3 99 63 4,652,949 2,587,514 53 86 177
Colonoscopy strategies
(10-fold increased
rates of cardiovascular
complications)
No screening 0 0 0 30 0 52 22 115 0 2,066,410 0 0 0 –
COL 45-55 y, 10 y 0 199 341 553 7 39 10 139 28 2,469,059 402,648 25 57 3
COL 45-55 y, 5 y 0 200 342 554 7 39 10 139 28 2,469,686 403,276 25 57 10
COL 40-55 y, 5 y 0 324 591 923 9 34 7 129 42 2,641,176 574,766 36 70 14
COL 35-55 y, 5 y 0 607 838 1451 11 31 5 122 51 3,075,548 1,009,138 41 76 49
COL 35-55 y, 3 y 0 642 1265 1911 13 26 4 110 55 3,406,590 1,340,180 49 81 85
COL 30-55 y, 3 y 0 1511 1825 3339 16 25 3 99 62 4,691,373 2,624,962 53 85 194
COL, colonoscopy; CRC, colorectal cancer; FIT, fecal immunochemical test; LY, life-years; LYG, LY gained compared with no screening; ICER, Incremental cost-
effectiveness ratio (costs/LYs gained).
NOTE. Bold rows indicate optimal screening strategies.
aIncluding deaths from complications of screening.
bCompared with no screening.
cCRC cases and CRC death were not discounted.
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Bars indicate 95% CIs. CRC = colorectal cancer; SEER = Surveillance, Epidemiology, and End Results.
Supplementary Figure 1. Colorectal cancer incidence seen before the introduction of screening vs incidence simulated by
MISCAN-Colon model.
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Supplementary Figure 2. Adenoma prevalence seen in
selected autopsy studies vs prevalence simulated by
MISCAN-Colon model. Observed results are shown only for
the 2 largest studies on which the model has been calibrated.
The model has additionally been calibrated to 8 other autopsy
studies. Bars indicate 95% CIs.
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Supplementary Figure 3. Adenoma and advanced adenoma detection rate simulated with Microsimulation Screening
Analysis-Colon (MISCAN-Colon model) and observed in a colonoscopy observational study among cystic ﬁbrosis patients.
February 2018 Cost Effectiveness of Screening Individuals With Cystic Fibrosis for CRC 567.e14
30-34 35-39 40-44 45-49 50-54 55-59 > 60C
R
C
 in
ci
de
nc
e 
ra
te
 (p
er
 1
,0
00
 p
er
so
n-
ye
ar
s)
0
10
20
30
40
US population Non-transplant CF patients (B)
Transplant CF patients (B)Non-transplant CF patients (S)
Transplant CF patients (S) As expected from Maisonneuve et al. 2013
Supplementary Figure 4. CRC incidence expected in cystic
ﬁbrosis individuals according to Maisonneuve et al; 2013 and
CRC incidence simulated in MISCAN-Colon model without
screening in the US general population, non-transplant, and
transplant CF patients assuming higher CRC risk through a
combination of a more frequent adenoma onset and a faster
adenoma progression (sensitivity analysis). Note: Bars indi-
cate 95% CIs; CRC, colorectal cancer; CF, cystic ﬁbrosis;
B, base case analysis; S, sensitivity analysis.
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MISCAN-Colon Model Description
(Model)
General Model Structure
MISCAN-Colon is a stochastic microsimulation model for
CRC that is useful in explaining and predicting trends in CRC
incidence and mortality rates and to assess the effects and
costs of primary prevention and screening for CRC.17
The model simulates the life history of each person at an
individual level, rather than as proportions of a cohort. For
that reason, the model allows the time dependence between
future and past state transitions. However, in contrast to
most traditional Markov models, MISCAN-Colon does not
use yearly transition probabilities, rather it generates
durations in states. This solution increases the model ﬂex-
ibility and computational performance. In addition, the
model simulates sequences of events by drawing from
distribution of probability or durations, rather than using
ﬁxed values. Hence, the results of the model are subject to
random variation.
MISCAN-Colon consists of 3 modules: a demography
module, natural history module, and screening module.
The Demography Module
The MISCAN-Colon model draws a date of birth and a
date of no-CRC death for each individual simulated, using
birth and life tables (representative of the population under
consideration). The model restricts the maximum age a
person can achieve to 100 years.
The Natural History Module
As each simulated person ages, 1 or more adenomas
may develop (Supplementary Figure 5). These adenomas
can be either progressive or non-progressive and both can
grow in size from small (<5 mm) to medium (6–9 mm) and
then to large (> 10 mm). Only progressive adenomas can
develop into preclinical cancer, which may progress
through stages I to IV. However, during each stage, CRC may
be diagnosed because of symptoms. After CRC clinical
diagnosis, survival time is simulated using age-, stage-, and
localization-speciﬁc survival estimates for clinically diag-
nosed CRC based on a study published by Rutter and
colleagues.19 For synchronous CRCs, survival is based on
the most advance cancer. The date of death for CRC patients
is the earliest simulated date of death (because of CRC or
another cause).
The probability of adenoma onset differs among the
individuals and depends on the person’s age and risk index.
For that reason, most persons do not develop adenomas
and some others develop many. The distribution of
adenoma over the colon and rectum was assumed equal to
the distribution of cancer cases seen in SEER before the
introduction of screening.38 The personal risk index and the
age-speciﬁc onset of adenomas were calibrated to adenoma
prevalence data obtained in several autopsy studies
(Supplementary Figure 2).21–30,38 Furthermore, the
age-speciﬁc probability of adenoma progressivity and the
age- or localization-speciﬁc transition between preclinical
and clinical cancer stages were calibrated to SEER data on
age-, stage-, and localization-speciﬁc incidence of CRC in
pre-screening years (ie, 1975–1979, Supplementary
Figure 1).38 The average duration of the preclinical cancer
stages were calibrated according to data obtained from
randomized, controlled trials (RCTs) evaluating screening
using guaiac fecal occult blood tests.10,11,14 The average
duration between adenoma onset and progression into
preclinical cancer (adenoma dwell time) was calibrated to
the data on interval cancer seen in a sigmoidoscopy
screening RCT.9 Furthermore, we assumed: an equal overall
dwell time for adenoma developing into cancer from
medium (30% of all CRCs) and from large-size adenomas
(70% of all CRCs); exponential distribution for all duration
in the adenoma and preclinical cancer phases; perfect cor-
relation for the durations within adenoma and preclinical
cancer (quicker growing from small adenoma and medium-
sized adenoma, quicker developing into preclinical CRC);
absence of correlation between durations in the adenoma
phase and duration in the preclinical cancer phase.
The Screening Module
Screening will modify some of the simulated life his-
tories. Some cancer cases will be prevented by the detection
and removal of adenomas or by detection in an earlier stage
(favorable survival). As seen in RCTs on guaiac fecal occult
blood testing, the stage-speciﬁc survival of screen-detected
CRC was more favorable compared with clinically detected
CRC, even after the lead-time bias correction.12 Hence, we
assigned those screen-detected cancer cases - that without
screening would have been clinically detected in the same
stage – a survival corresponding to a cancer that is 1 stage
less progressive. The only exceptions were screen-detected
stage IV cancer cases: we assigned the survival of a clini-
cally diagnosed stage IV cancer. Furthermore, together with
the positive effects of screening, we also modelled over-
diagnosis, overtreatment, and colonoscopy-related
complications.36
Integrating Modules
For each person simulated, a date of birth and a date of
no-CRC death (a lifetime history without adenoma or CRC)
are generated from the demography module. In patient A in
Supplementary Figure 6, the natural history module gener-
ates an adenoma. This adenoma progresses into preclinical
cancer (diagnosed as stage II CRC because of symptoms) and
results in CRC death before non-CRC death would have
occurred. However, in the screening module, a screening
examination is introduced: the adenoma is detected,
removed, and the CRC death prevented. The positive effect of
the screening intervention is indicated by the green arrow
and represents the increased LYG for this patient because of
screening. Another example is patient B, who develops an
adenoma that would never have been diagnosed in a
no-screening scenario. However, during the screening
examination, CRC is screen-detected in stage I and - for this
patient - screening results in overdiagnosis and overtreatment
of CRC (no LYG, but only additional LYs with CRC care).
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Results for US General Population (Included in
this Study)
According to the MISCAN-Colon model, up to 73% of
CRC deaths may be avoided by introducing CRC screening
in the US general population (Table 1). While this result
may appear elevated considering the ﬁndings of several
RCTs,9,15–17 it is in accordance with assumptions made in
our analysis. We investigated the impact of screening in
the entire colorectum with 100% adherence to screening
(in each screening round) and surveillance tests. The
RCTs mainly investigated the effect of screening on the
left colon (once-only ﬂexible sigmoidoscopy), reporting a
22%–31% reduction in CRC mortality with a compliance
ranging from 58% to 71%.9,15,17 Schoen et al reported a
50% reduction in distal CRC mortality in those invited to
ﬂexible sigmoidoscopy (54% of adherence in those
invited to repeat screening every 5 or 3 years).16
Furthermore, the MISCAN-Colon model is calibrated and
validated against data from the UK ﬂexible sigmoidos-
copy screening trial.34
Supplementary Figure 5. The general model structure of the MISCAN-Colon model.
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Supplementary Figure 6. Integrating modules with 2 examples.
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